We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis.
- Authors
Mazumder, Srestha; McCann, Heather; D'Silva, Susan; Furlong, Sarah; Shepherd, Claire E; Kril, Jillian J; Halliday, Glenda M; Rowe, Dominic B; Kiernan, Matthew C; Tan, Rachel H
- Abstract
The glutamate modulator, riluzole, extends survival in amyotrophic lateral sclerosis (ALS) and was recently assessed in a clinical trial for Alzheimer's disease (Ad).[1] This trial found that riluzole-treated patients with Ad had a significantly reduced decline of cerebral glucose metabolism in multiple Ad predilection brain regions compared to placebo, which correlated with cognitive performance.[1] Importantly however, assessment of amyloid load was not included in the trial and as such, the effect of riluzole treatment on Ad neuropathological changes in patients remains to be clarified. The severity of neuritic plaques were graded according to the neuritic plaque score of (A) C1: sparse (1-5 neuritic plaques per mm2); (B) C2: moderate (>=6 neuritic plaques per mm2); and (C) C3: frequent (>=20 neuritic plaques per mm2).
- Subjects
AMYLOID plaque; AMYOTROPHIC lateral sclerosis; CEREBRAL amyloid angiopathy; POSTMORTEM changes; RILUZOLE
- Publication
Brain: A Journal of Neurology, 2023, Vol 146, Issue 3, pe17
- ISSN
0006-8950
- Publication type
Article
- DOI
10.1093/brain/awac467